134 related articles for article (PubMed ID: 1721272)
1. Strategy of FK 506 therapy in liver transplant patients: effect of graft function.
Abu-Elmagd KM; Fung JJ; Alessiani M; Jain A; Takaya S; Venkataramanan R; Warty VS; Shannon W; Todo S; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2771-4. PubMed ID: 1721272
[No Abstract] [Full Text] [Related]
2. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients.
Millis JM; Bruce DS; Newell KA; Piper JB; Woodle ES; Seaman DS; Baker AL; Hart J; Dasgupta K; Thistlethwaite JR
Transplant Proc; 1996 Apr; 28(2):1014. PubMed ID: 8623213
[No Abstract] [Full Text] [Related]
3. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
4. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.
Winkler M; Ringe B; Jost U; Gubernatis G; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2688-90. PubMed ID: 7689277
[No Abstract] [Full Text] [Related]
5. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients.
D'Alessandro AM; Kalayoglu M; Pirsch JD; Corwith C; Knechtle SJ; Reed A; Belzer FO
Transplant Proc; 1991 Dec; 23(6):2987-8. PubMed ID: 1721335
[No Abstract] [Full Text] [Related]
6. Use of FK 506 for treatment of chronic rejection after liver transplantation.
Winkler M; Ringe B; Gerstenkorn C; Rodeck B; Gubernatis G; Wonigeit K; Pichlmayr R
Transplant Proc; 1991 Dec; 23(6):2984-6. PubMed ID: 1721334
[No Abstract] [Full Text] [Related]
7. Conversion to rescue therapy with FK 506: data from eight liver transplant patients.
Reggiani P; Orsenigo R; Gatti S; Albani AP; Ferla G; Doglia M; Fassati LR; Galmarini D
Transplant Proc; 1994 Dec; 26(6):3597-8. PubMed ID: 7527982
[No Abstract] [Full Text] [Related]
8. FK 506 versus cyclosporine in pediatric liver transplantation.
Tzakis AG; Reyes J; Todo S; Green M; Ohya T; Jain A; Abu-Elmagd K; Alessiani M; Fung JJ; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3010-5. PubMed ID: 1721343
[No Abstract] [Full Text] [Related]
9. FK 506 treatment of intractable rejection after liver transplantation.
Jost U; Winkler M; Ringe B; Rodeck B; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
[No Abstract] [Full Text] [Related]
10. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
[TBL] [Abstract][Full Text] [Related]
11. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.
Abu-Elmagd KM; Fung J; Draviam R; Shannon W; Jain A; Alessiani M; Takaya S; Venkataramanan R; Warty VS; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2767-70. PubMed ID: 1721271
[No Abstract] [Full Text] [Related]
12. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
[No Abstract] [Full Text] [Related]
13. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.
Takaya S; Bronsther O; Abu-Elmagd K; Ramos H; Fung JJ; Todo S; Starzl TE
Transplant Proc; 1993 Jun; 25(3):2381-5. PubMed ID: 7685953
[No Abstract] [Full Text] [Related]
14. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
15. FK 506 rescue therapy: early conversion improves efficacy.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
[No Abstract] [Full Text] [Related]
16. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.
Jain AB; Todo S; Fung JJ; Venkataramanan R; Day R; Bryant J; Abu-Elmagd KM; Alessiani M; Takaya S; Tzakis A
Transplant Proc; 1991 Dec; 23(6):3023-5. PubMed ID: 1721347
[No Abstract] [Full Text] [Related]
17. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
[No Abstract] [Full Text] [Related]
18. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates.
Gotoh M; Monden M; Kanai T; Umeshita K; Wang K; Ukei T; Dono K; Tono T; Murata M; Tanimoto J
Transplant Proc; 1991 Dec; 23(6):3265-8. PubMed ID: 1721431
[No Abstract] [Full Text] [Related]
19. FK 506 as treatment of late acute rejection in liver transplant patients.
Rucay P; Samuel D; Farges O; Reynes M; Bismuth H
Transplant Proc; 1995 Feb; 27(1):1105-6. PubMed ID: 7533354
[No Abstract] [Full Text] [Related]
20. FK 506 rescue therapy for intractable liver allograft rejection.
Wong P; Devlin J; Gane E; Ramage J; Portmann B; Williams R
Transpl Int; 1994; 7 Suppl 1():S70-6. PubMed ID: 11271339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
